Federal Pharmaceuticals (03933): UBT48128 tablets (overweight or obese) obtained implied approval for clinical trials of new drugs in China

Zhitongcaijing · 2d ago

Zhitong Finance App News, Federal Pharmaceutical (03933) issued an announcement. UBT48128 tablets, a Class 1 innovative drug independently developed by Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., a wholly-owned subsidiary of the company, have obtained implied approval from the China National Drug Administration for clinical trials of new drugs. The acceptance numbers are CXHL2601252, CXHL2601253 and CXHL2601254.

UBT48128 tablets are small molecule glucagon-like peptide-1 (GLP-1) receptor agonists. Through multiple mechanisms such as promoting insulin secretion, controlling appetite, and regulating energy metabolism, oral administration once a day can reduce blood sugar and weight loss, helping to improve patient compliance. Preclinical studies in various animal models have shown that UBT48128 can significantly reduce body weight, and the weight loss effect is superior to that of test control agents. This product is expected to show good therapeutic potential and provide new treatment options for overweight or obese patients.

UBT48128 tablets were approved for clinical trials of new drugs by the US Food and Drug Administration (“FDA”) on August 11, 2026.

In the future, the company will continue to work on new product research and development, and focus on enhancing competitiveness and creativity in the biomedical industry, deepening the field of chronic disease treatment, serving clinical trials and benefiting patients with better products and better pipelines, which is expected to generate greater benefits for the company and its shareholders.